TFX Teleflex Incorporated

Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details

Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details

WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on Thursday, November 6, 2025.

To participate in the conference call, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, .

An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 6, 2025, either on the Teleflex website or by telephone. The call can be accessed by dialing 1 800 770 2030 (U.S. and Canada) or 1 609 800 9909 (all other locations). The conference ID is 69028.

Vascular Intervention Virtual Meeting

On November 14, 2025, at 8:00 am Eastern Time, Teleflex will host a virtual meeting to review its recent Vascular Intervention business acquisition, with a focus on the strategic rationale and the comprehensive coronary and peripheral product portfolio.

To participate in the investor event, please utilize this to pre-register and receive the dial-in information. The call can also be accessed through a live audio webcast on the company’s website, .

About Teleflex Incorporated

As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the most trusted partner in healthcare, we offer a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access, and urology. We believe that the potential of great people, purpose driven innovation, and world-class products can shape the future direction of healthcare.

Teleflex is the home of Arrow™, Barrigel™, Deknatel™, LMA™, Pilling™, QuikClot™ Rüsch™, UroLift™ and Weck™ – trusted brands united by a common sense of purpose.

At Teleflex, we are empowering the future of healthcare. For more information, please visit .

Contacts:

Teleflex Incorporated:

Lawrence Keusch

Vice President, Investor Relations and Strategy Development



610-948-2836



EN
16/10/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Teleflex Incorporated

 PRESS RELEASE

Teleflex Announces Leadership Transition

Teleflex Announces Leadership Transition Stuart Randle Appointed Interim President and CEO Board Initiates Search for Permanent CEO Dr. Stephen Klasko Appointed Chairman of the Board Company Provides Update on Preliminary Full Year 2025 Revenue Results WAYNE, Pa., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) today announced that Stuart Randle, a member of the Company’s Board of Directors, has been appointed Interim President and Chief Executive Officer, effective immediately. Mr. Randle succeeds Liam Kelly, who departs as Chairman, President and CEO of the Compa...

Teleflex Incorporated - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Teleflex Incorporated: Update following revision of outlook to stable

Our credit view of this issuer reflects its very good liquidity and strong free cash flow, constrained by its highly competitive industry sector.

Teleflex Incorporated - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

Moody's Ratings revises Teleflex's outlook to stable, affirms Ba1 CFR,...

Moody's Ratings (Moody's) affirmed the ratings of Teleflex Incorporated ("Teleflex") including the Ba1 Corporate Family Rating (CFR), Ba1-PD Probability of Default Rating (PDR) and the Ba2 rating on the senior unsecured notes. The company's Speculative Grade Liquidity Rating (SGL) was unchanged at S...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch